Kristin Brooks, Contract Pharma || May 19, 2015 Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain
Kristin Brooks, Contract Pharma || May 7, 2015 Pharma teamed up with ICON, Tufts CSDD and other industry players to author new book detailing holistic reforms for trial design, clinical ops, and portfolios
Tim Wright, Editor || May 6, 2015 Herein are the results of our 2015 Annual Outsourcing Survey, where we call on you, the readers, to help us benchmark the state of the pharmaceutical outsourcing industry.
Kristin Brooks, Contract Pharma || April 1, 2015 KPMG Strategy’s Mark Ginestro discusses the impact of biosimilars after the FDA’s recent approval of filagrastim, and what drug makers should anticipate
Alex McClung, Xcelience || November 13, 2014 Getting packaged investigational materials dispensed to the patients taking part in clinical trials, on time and correctly, requires orchestrating myriad activities. This is the second in a series of articles outlining specific quality concerns associated with packaging clinical trial supplies and how to effectively manage those concerns.
Kristin Brooks, Associate Editor || October 14, 2014 While expensive and difficult to produce, Big Pharma is investing, looking to overcome the obstacles to development and commercialization that remain